RARA Antibody
- Known as:
- RARA Antibody
- Catalog number:
- abx000697
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- RARA Antibody
Related genes to: RARA Antibody
- Gene:
- RARA NIH gene
- Name:
- retinoic acid receptor alpha
- Previous symbol:
- -
- Synonyms:
- RAR, NR1B1
- Chromosome:
- 17q21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1988-06-09
- Date modifiied:
- 2019-04-23
Related products to: RARA Antibody
Related articles to: RARA Antibody
- A 69-year-old man with acute promyelocytic leukemia in molecular remission and no detectable PML::RARA transcripts in his peripheral blood cells developed acute otitis media. After 10 months, tympanomastoidectomy was performed for suspected secondary cholesteatoma. A histological examination confirmed extramedullary relapse with PML::RARA-positive cell infiltration. The patient achieved a second molecular remission after treatment with arsenic trioxide. Our findings suggest that (1) a diagnostic sample may be obtained from mastoid air cells rather than from the middle ear cavity, (2) molecular remission does not preclude extramedullary relapse, and (3) all-trans retinoic acid and arsenic trioxide combination therapy may reduce the risk of extramedullary relapse. - Source: PubMed
Publication date: 2026/09/29
Tsuge NorikoKobayashi TaisukeKomori MasahiroMurakami IchiroNegishi TatsuyaShigeto ShoheiTsunaga YutaOhara KeitoWatanabe ShinichiroYoshida ShoheiKojima Kensuke - Acute promyelocytic leukemia (APL) is a hematologic emergency characterized by a high risk of coagulopathy that can manifest with both severe bleeding and thrombotic events, including ischemic stroke. However, its initial presentation as large vessel arterial thrombosis is infrequent and potentially lethal. We report the case of a previously healthy 15-year-old female referred for suspected left frontal ischemic stroke with right spastic hemiplegia and expressive aphasia. One week earlier, she had presented with headache, nausea and transient episodes of paresthesias and weakness of the right hand and foot. Laboratory studies revealed bicytopenia (leukopenia and anemia), hypofibrinogenemia and elevated D-dimer. Imaging studies showed a subacute infarct in the left caudate nucleus and recent ischemia in the frontal cortex with complete occlusion of the left internal carotid artery. Bone marrow aspirate showed blast cells with Auer rods and strong positivity for myeloperoxidase. Flow cytometry revealed 41,2 % of cells with a phenotype compatible with promyelocytes, PML::RARA fusión gene was confirmed by molecular and cytogenetic studies. Immediate treatment with all-trans retinoic acid (ATRA), corticosteroids, and hemostatic support was initiated. Subsequently, the patient presented with a new occipital infarction and was started on anticoagulant therapy. She did well with motor and speech recovery. This case highlights the importance of considering APL as an underlying etiology of arterial thrombotic events in adolescents with cytopenias and coagulopathy, especially in the presence of major vessel occlusion, where early diagnosis and timely treatment are essential to reduce morbidity and mortality. - Source: PubMed
Publication date: 2026/08/24
Tarchini MalenaHerrera Andino María LauraHollmann Carlos HernanLópez Orozco MilagrosMás María EmiliaLlorens AldanaBrochero NatachaRivoire Juan ManuelArgüello Zamarbide María LourdesAballay Andrea MilagrosRicchi Brenda NidiaFiora María BelénSalazar Florencia CelesteColussi Yuliana SofíaEckhardt Andrea AlejandraSaad Emanuel José - Acute myeloid leukemia (AML) is characterized by high genotypic and immunophenotypic heterogeneity. We collected an extensive dataset containing 5366 flow cytometry files from 885 AML patients, stained with the EuroFlow acute leukemia orientation tube (ALOT) and AML/MDS panel, acquired in a standardized way at eight centers over a period of 10 years. Unsupervised clustering identified groups of patients based on FlowSOM-derived cell population percentages. In addition, we investigated immunophenotypic patterns in World Health Organization (WHO) patient classes and NPM1 subclasses, both at the cell population and the individual marker level. Some WHO classes, for example, AML with t(8;21)(q22;q22)/RUNX1::RUNX1T1 or t(15;17)(q24;q21)/PML::RARA, showed homogeneous immunophenotypes. Characterization of maturation arrest using FlowSOM confirmed maturation arrest at early stages in distinct WHO classes. Finally, a machine learning model was trained to predict WHO genetic classes from immunophenotypic data. The model allowed accurate prediction in 77% of cases, reproducible in an independent validation cohort. In conclusion, we show that EuroFlow standardized protocols allow analysis of multi-centric data measured over an extended period of time. Computational analysis demonstrated inter- and intrapatient immunophenotypic heterogeneity and allowed prediction of genetic abnormalities. - Source: PubMed
Publication date: 2026/09/29
Bonte SarahOlsman RosanVan Gassen SofieMatarraz SergioVillamor NeusNierkens StefanFernandez Paulada Costa Elaine SobralAanei Carmen-MarianaOrfao Albertovan Dongen Jacques J MSaeys YvanHofmans Mattiasvan der Velden Vincent H J - - Source: PubMed
Publication date: 2026/09/22
Wu Hsin ChiehLaplantine EmmanuelEsnault CécileNiwa-Kawakita MichikoZhang YiDe Almeida Bastos VivianeGeoffroy Marie-Claudede Thé Hugues - RARA overexpression defines a molecularly distinct subset of acute myeloid leukemia (AML). Tamibarotene, an oral selective RARA agonist, synergizes with azacitidine (AZA) but its addition to venetoclax (VEN) with AZA has not been assessed. SY-1425-202 was a multicenter, open-label, randomized study evaluating tamibarotene combined to VEN/AZA (TAMI/VEN/AZA) vs VEN/AZA alone in newly diagnosed RARA-positive, unfit AML. Part 1 assessed the safety of TAMI/VEN/AZA, part 2 randomized participants to TAMI/VEN/AZA vs VEN/AZA, and part 3 explored salvage therapy with TAMI/VEN/AZA after VEN/AZA failure in part 2. TAMI 6 mg twice daily was administered. Randomization occurred after confirmation of RARA positivity by cycle 1, day 8. The primary end point was complete remission (CR) + CR with incomplete hematologic recovery (CRi) in part 2 and part 3, and safety in part 1. In part 1 (n=10), overall response rate (ORR) was 77.8% (5 CR, 2 CRi). In part 2 (n=51), CR/CRi was 60.0% for TAMI/VEN/AZA and 69.2% for VEN/AZA. Median CR/CRi duration was 293 vs 253 days. ORR was 80.0% vs 73.1%, respectively. In part 3, 2 of 5 patients responded (CR, morphologically leukemia-free state). Grade ≥3 treatment-emergent adverse event occurred in 76% of patients. Deaths were attributed mainly to disease progression or known complications of therapy; none were attributed to TAMI. The study met prespecified futility criteria and was discontinued early. The addition of TAMI to VEN/AZA was tolerable but did not improve efficacy over VEN/AZA. These results did not demonstrate clinical benefit of TAMI in the frontline unfit RARA-positive AML setting receiving VEN/AZA. This trial was registered at www.clinicaltrials.gov as #NCT04905407. - Source: PubMed
Publication date: 2026/07/28
Cluzeau ThomasBorate UmaMcMahon ChristineFenaux PierreHeiblig MaelPeterlin PierreBall BrianChantepie SylvainEghtedar AlirezaKambhampati SumanSolh MelhemTorregrosa-Diaz JoseBraun ThorstenDugan JamesFeld JonathanGourin Marie-PierrePigneux ArnaudRobin Jean-BaptisteSchiller GaryStein EytanRoth DavidKelly MichaelPollyea Danielde Botton Stephane